Business Wire

o9 Solutions Continues Rapid International Growth

Share

o9 Solutions, the premier AI-powered platform for next-generation integrated business planning and decision-making for the enterprise, is continuing to experience rapid worldwide expansion. The Dallas-based software company, which has its sights set on being the ‘digital brain of every enterprise’ has reached 1,000 employees worldwide and expects to grow up to 1,500 employees in 2021. o9 Solutions’ fast growth comes as it grows its customer engagements, with new clients such as Estee Lauder, Avon, Pirelli, Kraft Heinz, and many others.

In September 2018, o9 opened its first office in the Netherlands to start its European expansion. Currently, o9 has 150+ employees across ten countries in Europe with offices in The Netherlands, Spain, Poland, Italy, France, Germany, Sweden, and the United Kingdom. That is an increase of 161% compared to Q1 2020. In the Asia Pacific region, o9 currently employs 45 people, an 164% increase compared to Q1 2020, and is due to open its first Singapore office soon.

o9’s fast growth is also recognized by the Financial Times which listed the company as one of the Americas Fastest Growing Companies 2021 as well as by Inc. magazine which recently ranked o9 as one of the fastest growing private companies in Texas.

Co-founder and CEO Chakri Gottemukkala says, "Despite the current business uncertainty, customers have continued to engage with us, helping drive our rapid international growth. We are very pleased to have been able to hire and develop such a great pool of talent - all committed to achieving success for our customers and who take pride in spurring the narrative around o9’s Digital Brain forward: our AI-driven, integrated, cloud-native platform that’s helping Fortune 500 businesses make better decisions, plan more effectively, and make better use of the earth’s resources.”

“We are focusing on creating a large, sustainable ecosystem where our o9 global organization will serve as an enabler of a much larger pool of skills and capabilities across partners, both consulting and technology. We continue to rapidly grow our partner network and since 2020 have certified more than a thousand consultants as o9 implementers. We expect to double that in 2021, with a high quality program focused on delivering certifications in technical skills of architecting and configuring the o9 platform as well as advanced analytics skills in ML and big data analytics that are integral part of o9 solutions that we deliver to our clients,” says Igor Rikalo, President and COO of o9.

About o9 Solutions

o9 Solutions is the premier AI-powered platform for integrated business planning and decision-making for the enterprise. Whether it is driving demand, aligning demand and supply, or optimizing commercial initiatives, any planning process can be made faster and smarter with o9’s AI-powered digital solutions. Bringing together technology innovations—such as graph-based enterprise modelling, big data analytics, advanced algorithms for scenario planning, collaborative portals, easy-to-use interfaces and cloud-based delivery—into one platform. For more information, please visit www.o9solutions.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Evelien van der Wel
PR Manager
+31 611737049
press@o9solution.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Celltrion Healthcare presents the first real-world data for Truxima® (biosimilar rituximab) in patients with diffuse large B-cell lymphoma at the EHA 2021 Virtual Congress12.6.2021 18:45:00 EEST | Press release

Celltrion Healthcare today presented new data from its post-approval study evaluating the real-world clinical effectiveness and safety of Truxima® (biosimilar rituximab, CT-P10) in patients with diffuse large B-cell lymphoma (DLBCL) at the European Hematology Association (EHA) 2021 Virtual Congress.1 CT-P10 was granted European Medicines Agency approval in 2017 for the treatment of rheumatoid arthritis (RA) and specific blood cancers, including non-Hodgkin’s lymphoma (NHL).2 DLBCL is the most common subtype of NHL, representing an estimated 30-40% of adult cases.3,4,5,6 This non-interventional post-authorisation safety study (PASS) involved the collection of patient-level data from hospital medical records for patients with DLBCL who received CT-P10 treatment in five European countries (United Kingdom, Spain, France, Germany and Italy). CT-P10 treatment pattern data were collected retrospectively during the 30-month observation period and patients were selected based on the treatment t

 Janssen Announces Results from Phase 3 MAIA Study Showing Significant Overall Survival Benefits for Treatment with DARZALEX®▼ (daratumumab) in Patients with Newly Diagnosed Multiple Myeloma Who are Transplant Ineligible12.6.2021 10:01:00 EEST | Press release

The Janssen Pharmaceutical Companies of Johnson & Johnson announced overall survival (OS) results from the Phase 3 MAIA (NCT02252172) study showing the addition of DARZALEX® ▼(daratumumab) to lenalidomide and dexamethasone (D-Rd) resulted in a statistically significant survival benefit over lenalidomide and dexamethasone (Rd) alone in patients with newly diagnosed multiple myeloma (NDMM) who were ineligible for autologous stem cell transplant (ASCT) and were treated to progression.1 These data were featured in the European Hematology Association (EHA) 2021 Virtual Press Briefing and will be presented as a late-breaking abstract during the EHA Virtual Congress (Abstract #LB1901). The prespecified interim analysis for OS found that after a median follow-up of nearly five years (56.2 months), a 32 percent reduction in the risk of death was observed in the D-Rd treatment arm vs. Rd arm.1 Median OS was not reached in either arm [hazard ratio (HR): 0.68, 95 percent confidence interval (CI),

New Phase 3 Study Results Show IMBRUVICA® (ibrutinib)-Based Combination Regimen as an All-Oral Fixed-Duration Treatment Demonstrated Superior Progression-Free Survival in Adult Patients with Previously Untreated Chronic Lymphocytic Leukaemia12.6.2021 10:00:00 EEST | Press release

The Janssen Pharmaceutical Companies of Johnson & Johnson today announced primary results from the pivotal Phase 3 GLOW study (NCT03462719) evaluating fixed-duration IMBRUVICA® (ibrutinib) plus venetoclax (I+V) compared to chlorambucil plus obinutuzumab (Clb+O) for first-line treatment of elderly or unfit patients with chronic lymphocytic leukaemia (CLL). The study demonstrated superior progression-free survival (PFS) of a once-daily, all-oral, fixed-duration regimen of I+V versus Clb+O as first-line treatment of CLL; the study also showed improved duration of remission and significantly improved depth of remission.1 With I+V, undetectable minimal residual disease (uMRD) in peripheral blood (PB) was sustained by 85 percent of patients one year after end of treatment.1 The safety and tolerability profile of I+V was consistent with CLL treatment in an older population with comorbidities.1 These data were featured in the European Hematology Association (EHA) 2021 Virtual Press Briefing an

Alluzience®, the first ready-to-use BoNT-A neuromodulator, receives positive decision for use in Europe11.6.2021 12:53:00 EEST | Press release

Galderma today announced that Alluzience® has completed its European decentralized procedure resulting in a positive decision for the first ready-to-use neuromodulator, a wrinkle relaxing injection, in Europe. National approvals will now take place across the region in line with local processes in each country. Designed for precision, Alluzience® is a liquid form of botulinum toxin type A intended for use in adult patients as a treatment to temporarily improve the appearance of moderate to severe glabellar lines (vertical lines between the eyebrows), when the severity of these lines has an important psychological impact on the patient.1 "The introduction of Alluzience® marks a new era in treatment innovation for upper facial lines in Europe. Like many aspects of physical appearance, glabellar lines can have a significant impact on patients’ confidence and wellbeing. I’ve heard first-hand that the transition to living and working in a virtual world has only exacerbated these issues. As

Slots Capital on useampien pelaajien ulottuvilla kuin koskaan aiemmin11.6.2021 12:23:00 EEST | Tiedote

Slots Capital on yksi maailman suosituimmista nettikasinoista. Nyt se on useampien pelaajien ulottuvilla kuin koskaan aiemmin, kun sivusto on ensimmäistä kertaa käynnistänyt toimintansa useissa uusissa maissa. Tämä tarkoittaa, että pelaajat Belgiassa, Romaniassa, Kreikassa, Tanskassa, Suomessa, Irlannissa, Latviassa ja Luxemburgissa voivat nyt nauttia Slots Capitalin huippuluokan nettikasinokokemuksesta. Jos rakastat kolikkopelien pelaamista, Slots Capital on todellakin sinua varten tarjoten yli 300 peliä isoilta pelinkehittäjiltä, kuten Rival, Saucify, Dragon ja Qora. Itse asiassa lisäsimme hiljattain kolikko- ja pöytäpeliaulaamme pelejä suosituilta studioilta, kuten Rival Gamingilta, Dragon Gamingilta, Saucify Gamingilta ja Qora Gamingilta. Lisäämme pelejä myös Arrow's Edgelta tulevina viikkoina, mutta sillä välin pelaajat voivat kokeilla peliaulamme uusimpia pelejä kuten: Dead Beats Irish Wishes Lucky Macau Panda Playtime Sands of Space Twin Dragons Viking Victory Win Another Day Wr

Slots Capital Available to More Players Than Ever Before11.6.2021 12:21:00 EEST | Press release

Slots Capital, one of the most popular online casinos in the world, in now available to more players than ever before after launching into several new countries for the very first time. This means players in Belgium, Romania, Greece, Denmark, Finland, Ireland, Latvia and Luxembourg can now enjoy the top-rated online casino experience offered at Slots Capital. If you love playing slots, then Slots Capital really is the place to be. In fact, we recently boosted our slots and table games lobby with titles from in-demand studios including Rival Gaming, Dragon Gaming, Saucify Gaming and Qora Gaming. We will also be adding slots from Arrow’s Edge in the coming weeks but in the meantime, players can try the latest titles to hit our lobby including: Dead Beats Irish Wishes Lucky Macau Panda Playtime Sands of Space Twin Dragons Viking Victory Win Another Day Wrath of Medusa Yeti Hunt i3D Slots Capital is not only known for being the number one destination for slots, players also love our daily

Secure Communities Forum: Behavioural Insights Can Assist Governments in the Post-Pandemic World11.6.2021 11:15:00 EEST | Press release

The Secure Communities Forum, a global collaboration of security professionals, has convened a leading panel of experts to discuss how behavioural science can impact positive social cohesion, build on the concept of positive citizenship, and encourage positive individual behaviours. The virtual event was attended by 134 people from 18 countries. The Secure Communities Forum convened the webinar in response to the ongoing Covid-19 pandemic. Governments and law enforcement agencies have used behavioural science to encourage adherence to public health measures like social distancing and mask-wearing. Lindsay Juarez, Director at Irrational Labs, USA, opened the session, offering the view that we assume humans are rational, which is not the case. She said: “Behavioural science is about setting people up for success and breaking through the noise. Information isn't enough to change behaviour, the decision-making context matters. “People don’t always act in their own long-term best interests,

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom